The small HDL particle hypothesis of Alzheimer’s disease

We propose the hypothesis that small high‐density lipoprotein (HDL) particles reduce the risk of Alzheimer's disease (AD) by virtue of their capacity to exchange lipids, affecting neuronal membrane composition and vascular and synaptic functions. Concentrations of small HDLs in cerebrospinal fluid (CSF) and plasma were measured in 180 individuals ≥60 years of age using ion mobility methodology. Small HDL concentrations in CSF were positively associated with performance in three domains of cognitive function independent of apolipoprotein E (APOE) ε4 status, age, sex, and years of education. Moreover, there was a significant correlation between levels of small HDLs in CSF and plasma. Further studies will be aimed at determining whether specific components of small HDL exchange across the blood, brain, and CSF barriers, and developing approaches to exploit small HDLs for therapeutic purposes.

[1]  Caden M. Henningfield,et al.  Microglia‐specific ApoE knock‐out does not alter Alzheimer's disease plaque pathogenesis or gene expression , 2021, Glia.

[2]  H. Yassine,et al.  Understanding the Exchange of Systemic HDL Particles Into the Brain and Vascular Cells Has Diagnostic and Therapeutic Implications for Neurodegenerative Diseases , 2021, Frontiers in Physiology.

[3]  Brandon C Farmer,et al.  Lipid Droplets in Neurodegenerative Disorders , 2020, Frontiers in Neuroscience.

[4]  D. Holtzman,et al.  Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol , 2020, Proceedings of the National Academy of Sciences.

[5]  J. Santabárbara,et al.  Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis , 2020, Brain sciences.

[6]  A. Fagan,et al.  APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline , 2020, Nature.

[7]  C. Wellington,et al.  Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E , 2020, Molecular Neurodegeneration.

[8]  Robert C. Green,et al.  Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study , 2020, Nature Communications.

[9]  Y. Asmann,et al.  ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain , 2019, Proceedings of the National Academy of Sciences.

[10]  H. Chui,et al.  ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes , 2019, The Journal of Neuroscience.

[11]  D. Holtzman,et al.  Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model , 2019, The Journal of experimental medicine.

[12]  Jeffrey I. Jones,et al.  Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects. , 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  N. V. van Nuland,et al.  Apolipoprotein E associated with reconstituted high‐density lipoprotein‐like particles is protected from aggregation , 2019, FEBS letters.

[14]  Gianvito Grasso,et al.  The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the β-Amyloid Efflux Across the Blood-Brain Barrier in vitro , 2019, Front. Neurosci..

[15]  Genetic,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[16]  M. Mimura,et al.  The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up , 2019, Translational Psychiatry.

[17]  A. Fagan,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[18]  K. Blennow,et al.  CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients , 2017, Neurobiology of Aging.

[19]  A. Kontush,et al.  Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit , 2017, BBA clinical.

[20]  Jeffrey I. Jones,et al.  Simultaneous Quantification of Free Cholesterol, Cholesteryl Esters, and Triglycerides without Ester Hydrolysis by UHPLC Separation and In-Source Collision Induced Dissociation Coupled MS/MS , 2017, Journal of The American Society for Mass Spectrometry.

[21]  M. Fukumoto,et al.  Lysophosphatidylcholine export by human ABCA7. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[22]  F. Mastaglia,et al.  Serum high-density lipoprotein is associated with better cognitive function in a cross-sectional study of aging women , 2017, The International journal of neuroscience.

[23]  F. Leypoldt,et al.  Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma , 2017, Alzheimer's & dementia.

[24]  Jeffrey I. Jones,et al.  On-column trypsin digestion coupled with LC-MS/MS for quantification of apolipoproteins. , 2017, Journal of proteomics.

[25]  D. Holtzman,et al.  Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models , 2016, Neurobiology of Aging.

[26]  F. Berven,et al.  Label‐free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis , 2016, Proteomics.

[27]  H. Chui,et al.  ABCA1‐Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease , 2016, Journal of the American Heart Association.

[28]  B. Nordestgaard,et al.  Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease , 2015, Alzheimer's & Dementia.

[29]  D. Rader,et al.  Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. , 2015, Journal of the American College of Cardiology.

[30]  P. Ridker,et al.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial , 2015 .

[31]  J. Genest,et al.  Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro , 2015, PloS one.

[32]  G. Landreth,et al.  Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice* , 2015, The Journal of Biological Chemistry.

[33]  Huaxi Xu,et al.  Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice , 2015, Molecular Neurodegeneration.

[34]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[35]  J. Cirrito,et al.  Intravenously Injected Human Apolipoprotein A‐I Rapidly Enters the Central Nervous System via the Choroid Plexus , 2014, Journal of the American Heart Association.

[36]  M. Ikram,et al.  Cardiovascular risk factors and future risk of Alzheimer’s disease , 2014, BMC Medicine.

[37]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[38]  J. Poirier,et al.  Differential regulation of ABCA1 and ABCG1 gene expressions in the remodeling mouse hippocampus after entorhinal cortex lesion and liver-X receptor agonist treatment , 2014, Brain Research.

[39]  P. Reaven,et al.  Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. , 2014, Metabolism: clinical and experimental.

[40]  Ling Li,et al.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis , 2014, Journal of neurochemistry.

[41]  A. C. Kroksveen,et al.  Effects of Blood Contamination and the Rostro-Caudal Gradient on the Human Cerebrospinal Fluid Proteome , 2014, PloS one.

[42]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[43]  K. Moore,et al.  Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.

[44]  S. Woods,et al.  Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. , 2012, American journal of physiology. Regulatory, integrative and comparative physiology.

[45]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[46]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[47]  G. Landreth,et al.  Apolipoprotein E Promotes β-Amyloid Trafficking and Degradation by Modulating Microglial Cholesterol Levels* , 2011, The Journal of Biological Chemistry.

[48]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[49]  D. Rader,et al.  The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[50]  N. Seidah,et al.  ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD , 2010, Proceedings of the National Academy of Sciences.

[51]  Amy E. Sanders,et al.  Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. , 2010, JAMA.

[52]  K. Blennow,et al.  A survey of ABCA1 sequence variation confirms association with dementia , 2009, Human mutation.

[53]  D. Holtzman,et al.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. , 2008, The Journal of clinical investigation.

[54]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[55]  T. Terasaki,et al.  24S‐hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical‐ and apoE isoform‐dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression , 2007, Journal of neurochemistry.

[56]  A. von Eckardstein,et al.  Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. , 2006, Biochimica et biophysica acta.

[57]  M. Staufenbiel,et al.  Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* , 2005, Journal of Biological Chemistry.

[58]  M. Hayden,et al.  The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[59]  E. Schaefer,et al.  Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux Published, JLR Papers in Press, August 1, 2005. DOI 10.1194/jlr.M500187-JLR200 , 2005, Journal of Lipid Research.

[60]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[61]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[62]  A. Kontush,et al.  Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[63]  C. Göritz,et al.  CNS synaptogenesis promoted by glia-derived cholesterol. , 2001, Science.

[64]  C. Buhmann,et al.  Characterization of four lipoprotein classes in human cerebrospinal fluid. , 2001, Journal of lipid research.

[65]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[66]  D. Mangelsdorf,et al.  LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  R. Campenot,et al.  Uptake of Lipoproteins for Axonal Growth of Sympathetic Neurons* , 2000, The Journal of Biological Chemistry.

[68]  N. Cairns,et al.  Cholesterol Modulates the Membrane- Disordering Effects of Beta-Amyloid Peptides in the Hippocampus: Specific Changes in Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[69]  Ramsden,et al.  Fibroblast growth factor receptor expression investibular schwannoma , 2000, Clinical otolaryngology and allied sciences.

[70]  J. Vandekerckhove,et al.  Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. , 2000, Journal of lipid research.

[71]  G. Siest,et al.  Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease☆ , 2000, Neurobiology of Aging.

[72]  T. Katsuyama,et al.  Characterization of apolipoprotein E-containing lipoproteins in cerebrospinal fluid: effect of phenotype on the distribution of apolipoprotein E. , 1999, Clinical chemistry.

[73]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[74]  T. Montine,et al.  Apolipoprotein E allelic influence on human cerebrospinal fluid apolipoproteins. , 1998, Journal of lipid research.

[75]  Sara E. Miller,et al.  Novel Large Apolipoprotein E‐Containing Lipoproteins of Density 1.006–1.060 g/ml in Human Cerebrospinal Fluid , 1998, Journal of neurochemistry.

[76]  H. Wieland,et al.  Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype. , 1996, Biochimica et biophysica acta.

[77]  S. Young,et al.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. , 1991, The Journal of clinical investigation.

[78]  K. Weisgraber Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. , 1990, Journal of lipid research.

[79]  R. Cecchelli,et al.  Interactions of high-density lipoprotein 3 with brain capillary endothelial cells. , 1989, Biochimica et biophysica acta.

[80]  A. Chobanian,et al.  Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. , 1988, Journal of lipid research.

[81]  E. Gong,et al.  Molecular pathways in the transformation of model discoidal lipoprotein complexes induced by lecithin:cholesterol acyltransferase. , 1985, Biochimica et biophysica acta.

[82]  E. Gong,et al.  Characterization of human high-density lipoproteins by gradient gel electrophoresis. , 1981, Biochimica et biophysica acta.

[83]  T. Montine,et al.  Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[84]  J. Stockman Association of a Functional Polymorphism in the Cholesteryl Ester Transfer Protein (CETP) Gene With Memory Decline and Incidence of Dementia , 2011 .

[85]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[86]  R. Stelzmann,et al.  An english translation of alzheimer's 1907 paper, “über eine eigenartige erkankung der hirnrinde” , 1995 .